Vyden J K, Nagasawa K, Kanazawa M, Rose H B, Seino Y, Groseth-Robertson M F, Lander E B, Elconin S B
Angiology. 1984 Jan;35(1):1-11. doi: 10.1177/000331978403500101.
While cyclandelate is widely used in the therapy of peripheral arterial disease, objective evidence of its efficacy remains controversial. For this reason, 12 patients with intermittent claudication (average age of 66.8 years) received both cyclandelate 400 mg qid and placebo in a double-blind crossover trial lasting two months. During the cyclandelate and placebo periods, the following peripheral hemodynamic measurements were obtained using a plethysmograph and treadmill claudication testing: mean calf blood flow, vascular resistance and venous capacitance; finger and toe blood flow, pulsation amplitude and temperature before and after vasodilating maneuvers; arm and leg arterial pulsation amplitudes, one and ten minute calf reactive hyperemia reaction; 30 pound/30 second calf active hyperemia reactions and times of onset of claudication as measured on a treadmill. No major significant difference could be demonstrated between placebo and cyclandelate on any subjective symptom or any objective measurement. It is concluded that cyclandelate 400 mg qid for 4 weeks was of little objective value in treating this group of 12 patients with peripheral arterial disease and suffering from intermittent claudication.
尽管环扁桃酯广泛用于外周动脉疾病的治疗，但其疗效的客观证据仍存在争议。因此，在一项为期两个月的双盲交叉试验中，12例间歇性跛行患者（平均年龄66.8岁）同时接受了每日4次、每次400毫克的环扁桃酯和安慰剂治疗。在环扁桃酯和安慰剂治疗期间，使用体积描记器和跑步机进行间歇性跛行测试，获得了以下外周血流动力学测量结果：平均小腿血流量、血管阻力和静脉容量；血管舒张操作前后的手指和脚趾血流量、搏动幅度和温度；手臂和腿部动脉搏动幅度、小腿1分钟和10分钟反应性充血反应；30磅/30秒小腿主动充血反应以及在跑步机上测量的间歇性跛行发作时间。在任何主观症状或客观测量方面，安慰剂和环扁桃酯之间均未显示出重大显著差异。得出的结论是，对于这组12例患有外周动脉疾病并伴有间歇性跛行的患者，每日4次、每次400毫克的环扁桃酯治疗4周几乎没有客观价值。
